CD-PROBE: Cervical Dystonia Patient Registry for the Observation of onabotulinumtoxinA Efficacy
Completed
- Conditions
- Cervical Dystonia
- Interventions
- Other: No Intervention
- First Posted Date
- 2009-02-04
- Last Posted Date
- 2014-07-17
- Lead Sponsor
- Allergan
- Target Recruit Count
- 1046
- Registration Number
- NCT00836017
A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin
Completed
- Conditions
- Ocular Hypertension
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 50
- Registration Number
- NCT00834171
Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2011-10-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 171
- Registration Number
- NCT00834210
Dapsone Gel 5% and Tretinoin Gel 0.025% Versus Tretinoin Gel 0.025% Monotherapy for Facial Acne Vulgaris
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2011-10-31
- Lead Sponsor
- Allergan
- Target Recruit Count
- 163
- Registration Number
- NCT00835198
A Natural History Study of Patients With Dry Eye
Completed
- Conditions
- Dry Eye
- Interventions
- Other: Artificial Tears
- First Posted Date
- 2009-02-02
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 284
- Registration Number
- NCT00833235
- Locations
- 🇺🇸
Jones Eye Institute, Little Rock, Arkansas, United States
🇺🇸North Valley Eye Medical Group, Inc., Mission Hills, California, United States
🇺🇸Eye Center of Northern Colorado, Fort Collins, Colorado, United States
Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2012-09-12
- Lead Sponsor
- Allergan
- Target Recruit Count
- 165
- Registration Number
- NCT00829049
Physician's Evaluation of Cyclosporine Ophthalmic Emulsion 0.05%
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2019-04-25
- Lead Sponsor
- Allergan
- Target Recruit Count
- 35
- Registration Number
- NCT00827255
Comparison of the Fixed Combinations of Brimonidine/Timolol and Dorzolamide/Timolol in Subjects With Open-Angle Glaucoma or Ocular Hypertension
Phase 4
Completed
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- Drug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapyDrug: dorzolamide hcl 2%/timolol maleate 0.5% fixed combinationDrug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combinationDrug: brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2009-01-14
- Lead Sponsor
- Allergan
- Target Recruit Count
- 140
- Registration Number
- NCT00822055
An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects
Phase 4
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solutionDrug: latanoprost 0.005%
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2011-09-21
- Lead Sponsor
- Allergan
- Target Recruit Count
- 148
- Registration Number
- NCT00811564
Comparing Effects of Two Fixed Combinations Ophthalmic Solutions on Ocular Blood Flow
Phase 4
Completed
- Conditions
- Glaucoma
- Interventions
- Drug: fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solutionDrug: fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2019-04-24
- Lead Sponsor
- Allergan
- Target Recruit Count
- 15
- Registration Number
- NCT00811850
© Copyright 2025. All Rights Reserved by MedPath